<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040272</url>
  </required_header>
  <id_info>
    <org_study_id>MARS2</org_study_id>
    <nct_id>NCT02040272</nct_id>
  </id_info>
  <brief_title>Mesothelioma and Radical Surgery 2</brief_title>
  <acronym>MARS2</acronym>
  <official_title>Mesothelioma and Radical Surgery 2: a Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus no (Extended) Pleurectomy Decortication for Patients With Malignant Pleural Mesothelioma (Mars 2).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bristol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mesothelioma is a cancer of the thin membrane that lines the chest and abdomen. Around 2500
      people in the UK are diagnosed with mesothelioma each year and the median survival is
      approximately 8.5 months. Exposure to asbestos is the most common cause although the cancer
      does not usually become apparent until 40-60 years after exposure. Anti-cancer drugs
      (chemotherapy) are usually given to help treat mesothelioma and sometimes lung-sparing
      surgery (pleurectomy decortication) is undertaken. However, it is not known if this surgery,
      in addition to chemotherapy, can increase survival and improve the quality of life for
      patients. The aim of the MARS2 study is to compare surgery - (extended) pleurectomy
      decortication - with no surgery with respect to overall survival, cost-effectiveness and
      quality of life. Patients will be followed up by phone at regular intervals for 2 years.
      Patients will be asked to complete and return a Quality of Life Questionnaire at these time
      points.

      MARS 2 also includes an optional 'Information study', where consenting patients may be
      interviewed or have their consultations audio-recorded. The aim of the Information study is
      to explore how a patient makes a decision to take part in research or not, with the overall
      aim of improving recruitment to clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>24 months</time_frame>
    <description>The time from randomisation to death will be measured and date of death will be collected on purposely designed case report forms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival to two years</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse health events to two years after randomisation</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life: EORTC QLQ-C30 (questionnaire) to two years</measure>
    <time_frame>24 months</time_frame>
    <description>3 types of scales. Functioning scales which include physical functioning, role functioning, emotional function, cognitive functioning and social functioning. Symptom scales which include fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea, financial difficulties. An overall global health status/QoL
All scales range between 0 and 100.
For functioning scales, a high score indicates a high level of functioning. Similarly, a high global health status/QoL score indicates a high quality of life. For symptom scales, a high score indicates a high level of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource and health service use to two years and during initial surgical admission for surgical arm</measure>
    <time_frame>24 months and during initial surgical admission for surgical arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life: EQ-5D-5L (questionnaire) to two years</measure>
    <time_frame>24 Months</time_frame>
    <description>subscales: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. These range from 1-5.
subscales mobility, self-care, usual activities, pain/discomfort, anxiety/depression are combined to calculate an overall index score which ranges from -0.59 to 1.
A higher score indicates better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life: EQ-5D-5L (questionnaire) to two years</measure>
    <time_frame>24 months</time_frame>
    <description>VAS (visual analogue scale) score. Ranges from 0 to 100.
A higher score indicates better quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">328</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Extended) pleurectomy decortication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>(Extended) pleurectomy decortication</intervention_name>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. 16 years of age or over

          2. Tissue (cytology or histology) confirmed epithelioid, sarcomatoid or biphasic
             mesothelioma

          3. Disease confined to one hemi-thorax based on CT assessment

          4. Disease deemed surgically resectable

          5. Fit for surgery

          6. Capacity to provide written informed consent to participate in the trial

        Exclusion criteria:

          1. Severe shortness of breath (this is defined as an Eastern Cooperative Oncology Group
             (ECOG) status â‰¥ 2, or if lung function tests are performed: pre-operative forced
             expiratory volume after one second (FEV1) or transfer factor of the lung for carbon
             monoxide (TLco) less than 20%)

          2. Serious concomitant disorder that would compromise participant safety during surgery
             (e.g. evidence of end organ failure)

          3. Severe heart failure (this is defined as NYHA III or IV or if an echocardiogram is
             performed an ejection fraction less than 30%)

          4. End stage kidney failure requiring dialysis

          5. Liver failure (e.g. encephalopathy and/or coagulation abnormalities)

          6. Prisoner

          7. Patient lacks capacity to consent

          8. Existing co-enrolment in another interventional clinical trial that aims to improve
             survival
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Lim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Lim</last_name>
    <email>e.lim@rbht.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Study Mailbox</last_name>
    <email>Mars2-trial@bristol.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <state>Whitechapel</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Lau</last_name>
    </contact>
    <investigator>
      <last_name>Kelvin Lau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Middleton, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gary Middleton, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Bristol Trust</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Maskell</last_name>
    </contact>
    <investigator>
      <last_name>Nick Maskell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Papworth</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Rintoul</last_name>
    </contact>
    <investigator>
      <last_name>Robert Rintoul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colchester</name>
      <address>
        <city>Colchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dakshinamoorthy Muthukumar</last_name>
    </contact>
    <investigator>
      <last_name>Dakshinamoorthy Muthukumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derby</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manjusha Keni</last_name>
    </contact>
    <investigator>
      <last_name>Manjusha Keni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinton Ali</last_name>
    </contact>
    <investigator>
      <last_name>Clinton Ali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alan Kirk</last_name>
    </contact>
    <investigator>
      <last_name>Alan Kirk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Milton</last_name>
    </contact>
    <investigator>
      <last_name>Richard Milton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Fennell</last_name>
    </contact>
    <investigator>
      <last_name>Dean Fennell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Lau</last_name>
    </contact>
    <investigator>
      <last_name>Kevin Lau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bille, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Bille, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Popat</last_name>
    </contact>
    <investigator>
      <last_name>Sanjay Popat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maidstone and Tunbridge Wells NHS Trust</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riyaz Shah, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Riyaz Shah, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wythenshawe</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Taylor</last_name>
    </contact>
    <investigator>
      <last_name>Paul Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Tees</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talal Mansy</last_name>
    </contact>
    <investigator>
      <last_name>Talal Mansy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Tyneside NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Fuller</last_name>
    </contact>
    <investigator>
      <last_name>Liz Fuller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Gwent</name>
      <address>
        <city>Newport</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina Ionescu</last_name>
    </contact>
    <investigator>
      <last_name>Alina Ionescu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zacharias Tasigiannopoulos</last_name>
    </contact>
    <investigator>
      <last_name>Zacharias Tasigiannopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Najib M Rahman, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Najib M Rahman, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North West Anglia NHS Foundation Trust</name>
      <address>
        <city>Peterborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Treece</last_name>
      <email>hollyemilymckeon4@gmail.co</email>
    </contact>
    <investigator>
      <last_name>Sarah Treece</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Plymouth</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Roy, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Amy Roy, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Edwards</last_name>
    </contact>
    <investigator>
      <last_name>John Edwards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clatterbridge</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Pope</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Pope</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Cross</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Morgan</last_name>
    </contact>
    <investigator>
      <last_name>Ian Morgan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

